Ensysce Biosciences

ENSC

Market cap $6.89M

~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain therapeutics designed to minimize abuse and overdose risk, has released video highlights from its widely attended symposium at PAINWeek2025, the world's largest pain management conference. The event, titled "Pain Management, RE-Invented: A New Era for Analgesia," was held in Las Vegas on September 3, 2025, and featured a distinguished panel of medical and scientific leaders.

~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today shared key takeaways from its standing-room-only symposium with about 400 attendees, "Pain Management, RE-Invented: A New Era for Analgesia", held September 3, 2025, at PAINWeek in Las Vegas-the world's largest pain management conference. Moderated by Dr. Lynn Kirkpatrick, CEO of Ensysce, the event brought together three leading authorities in pain medicine: Dr. Jessica McCoun, Principal Investigator at CenExel Atlanta, opened with strategies for controlling acute post-operative pain using multi-modal therapy to prevent chronification, the gradual transition from acute pain to chronic pain.

~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver Opening Remarks and Present Case Study on Launching Successful Brands ~ SAN DIEGO, CA / ACCESS Newswire / August 19, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will chair the Fierce New Product Planning Summit 2025, held September 8-11, 2025 at the Pennsylvania Convention Center in Philadelphia. Mr. Birkett, recognized for his expertise in product launches and commercial strategy, will deliver the Opening Remarks, set the tone of the meeting, and present a case study on the launch process and how to maximize success.

New York, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business updates, management commentary, financial results, valuation, and risks.

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2025. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Momentum continued in the second quarter as we forged ahead progressing, what we believe will be the next evolution in opioid therapeutics: safety features built in to help guard against both misuse and overdose.

~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~ ~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits are Recognized ~ SAN DIEGO, CA / ACCESS Newswire / July 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical innovator focused on redefining opioid safety, today announced that it received positive feedback and constructive guidance from the U.S. Food and Drug Administration (FDA) on the development of PF614-MPAR, the Company's first-of-its-kind opioid analgesic designed with both abuse deterrence and overdose protection. PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.

~ FDA Protocol Review Completed ~ ~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the initiation of its pivotal Phase 3 study of PF614, the Company's lead product candidate. This landmark study, PF614-301, ‘A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after Abdominoplasty' is designed to demonstrate PF614's ability to effectively manage post-surgical pain while protecting from abuse and offering patients what is believed to be a safer alternative to conventional opioids.

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~ ~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology. PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.

~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced a world-class panel to discuss the current state of pain therapy at their planned scientific symposium to be held during PAINWeek 2025. PAINWeek is the largest pain conference in the world where experts meet to share knowledge to enhance patient care.

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA)1. This continued support will accelerate the clinical and non-clinical development of PF614-MPAR, a next-generation opioid designed to offer powerful pain relief while dramatically reducing the risk of overdose.